3-deazaneplanocin has been researched along with Lymphoma, Large B-Cell, Diffuse in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, P; Fan, Y; Fu, J; Li, B; Sun, Y; Wang, P; Xu, L; Zhang, X | 1 |
| Akpa, CA; Dimitrova, L; Hummel, M; Kleo, K; Lenze, D; Oker, E | 1 |
2 other study(ies) available for 3-deazaneplanocin and Lymphoma, Large B-Cell, Diffuse
| Article | Year |
|---|---|
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16.
Topics: B-Lymphocytes; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Humans; Lymphoma, Large B-Cell, Diffuse; Mutation | 2022 |
DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Topics: Adenosine; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Humans; Lymphoma, Large B-Cell, Diffuse; Mutation; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6; Proto-Oncogene Proteins c-myc; Translocation, Genetic | 2019 |